Exact Sciences Corporation reported significant financial performance improvements in its latest quarterly filing, with total revenue reaching $850.7 million for the three months ended September 30, 2025, a 20% increase from $708.7 million in the same period last year. For the nine months ended September 30, 2025, revenue was $2.37 billion, up 15.8% from $2.05 billion in 2024. The growth was primarily driven by increased demand for its Cologuard and Oncotype DX tests, with screening revenue rising by 22.3% and precision oncology revenue increasing by 12.7% year-over-year.
Despite the revenue growth, Exact Sciences reported a net loss of $19.6 million for the third quarter of 2025, an improvement from a net loss of $38.2 million in the same quarter of 2024. The company’s operating expenses also increased, totaling $609.5 million for the quarter, up from $534 million a year earlier, largely due to higher sales and marketing costs associated with expanding its product offerings. The gross profit margin slightly decreased to 68.6% from 69.4% in the prior year, attributed to increased production costs linked to higher test volumes.
Strategically, Exact Sciences launched its Cancerguard test, a multi-cancer early detection blood test, in September 2025, and expanded its ExactNexus technology platform, achieving 500 unique healthcare organization interface connections. The company also entered into a collaboration agreement with Freenome Holdings, which includes a $75 million upfront payment and potential milestone payments totaling $700 million based on future product developments. These initiatives are part of a broader strategy to enhance its product portfolio and increase market penetration.
Operationally, Exact Sciences reported a record number of orders and shipments in its gap closure program, which aims to improve preventive cancer screening rates. The company’s cash and cash equivalents increased to $789 million as of September 30, 2025, up from $600.9 million at the end of 2024. The company also reported cash provided by operating activities of $339.7 million for the nine months ended September 30, 2025, a significant increase from $163.5 million in the same period of 2024.
Looking ahead, Exact Sciences anticipates continued revenue growth driven by its existing and new product launches, including the Cologuard Plus and Oncodetect tests. The company is focused on enhancing patient adherence to screening and expanding its international presence, particularly in Japan. However, it acknowledges potential challenges from macroeconomic conditions and competition in the healthcare market. The company remains committed to its multi-year productivity plan, aiming for over $150 million in annual savings by 2026, which it believes will support its long-term growth objectives.
About EXACT SCIENCES CORP
Exact Sciences Corporation specializes in cancer screening and diagnostic tests, including non-invasive stool-based and blood-based assays, as well as precision oncology genomic profiling. Its core products, such as Cologuard and Oncotype DX, serve healthcare providers and patients worldwide, offering early detection, personalized treatment insights, and improved clinical outcomes. The company’s business model emphasizes innovation, regulatory approval, reimbursement strategies, and global commercialization in the rapidly evolving molecular diagnostics industry.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.